PDCD1 and triple-negative breast carcinoma: First, therapeutic strategies involving STAT3 inhibition could enhance the efficacy of anti-PD-L1/PD-1 monoclonal antibodies, which recently proved efficacy in patients with metastatic triple negative breast cancer [7].